首页 文献索引 SCI期刊 AI助手
首页 正文

Japanese journal of clinical oncology. 2025 Jan 16:hyae182. doi: 10.1093/jjco/hyae182 Q32.22025

First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia

一线帕博利珠单抗-阿昔替尼与舒尼替尼治疗转移性肾细胞癌：来自KEYNOTE-426三期临床试验的东亚人群亚组分析结果 翻译改进

Hsiao-Jen Chung  1  2, Chihiro Kondoh  3, Woo Kyun Bae  4, Satoshi Tamada  5, Nobuaki Matsubara  6, Hyo Jin Lee  7, Ryuichi Mizuno  8, Satoshi Anai  9, Go Kimura  10, Yoshihiko Tomita  11, Chao-Hsiang Chang  12, John Wen-Cheng Chang  13, Jianxin Lin  14, Rodolfo F Perini  14, L Rhoda Molife  15, Thomas Powles  16, Brian I Rini  17, Hirotsugu Uemura  18

作者单位 +展开

作者单位

  • 1 Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City, 11217, Taiwan.
  • 2 College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Daxue rd, East District, Taipei, 30010, Taiwan.
  • 3 Toranomon Hospital, 2 Chome-2-2 Toranomon, Minato City, Tokyo 105-8470, Japan.
  • 4 Chonnam National University Hospital and College of Medicine, Gwangju, Dong-gu, Baekseo-ro, 160, Hwasun, Republic of Korea.
  • 5 Osaka Metropolitan University, 599-8247 Higashiyama 500-3 Naka-ku, Sakai City, Osaka, Japan.
  • 6 National Cancer Center Hospital East, $/overline/top$277-8577 Chiba, Kashiwa, Kashiwanoha, 6 Chome-5-1, Japan.
  • 7 Chungnam National University School of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon, Republic of Korea.
  • 8 Keio University Hospital, 35 Shinanomachi, Shinjuku City, Tokyo 160-0016, Japan.
  • 9 Nara Medical University Hospital, 1 Chome-14-16 Mimuro, Sango, Ikoma District, Nara 636-0802, Kashihara, Japan.
  • 10 Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
  • 11 Niigata University Medical & Dental Hospital, 1 Bancho-754 Asahimachidori, Chuo Ward, Niigata, 951-8122, Japan.
  • 12 China Medical University Hospital, No. 2, Yude Road, North District, Taichung City 404327, Taiwan.
  • 13 Chang Gung University College of Medicine, No. 259, Wenhua 1st Rd, Guishan District, Taoyuan City, Taiwan 333, Taiwan.
  • 14 Merck & Co., Inc, 2025 E Scott Ave, 07065, Rahway, NJ, United States.
  • 15 MSD UK, 2 St Pancras Square, N1C 1AG, London, United Kingdom.
  • 16 Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, EC1M 6AU, London, United Kingdom.
  • 17 Cleveland Clinic Taussig Cancer Institute, 2220 Pierce Ave, 44195, Cleveland, OH, United States.
  • 18 Kindai University Hospital, 377-2 Onohigashi, Osakasayama, 589-8511, Osaka, Japan.

    • DOI: 10.1093/jjco/hyae182 PMID: 39815637

    摘要 Ai翻译

    Background: The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC) in a global population. This subgroup analysis investigated the efficacy and safety of pembrolizumab-axitinib versus sunitinib in patients enrolled in KEYNOTE-426 in East Asia (Japan, South Ko... ...点击完成人机验证后继续浏览
    Copyright © Japanese journal of clinical oncology. 中文内容为AI机器翻译，仅供参考！

    相关内容

    期刊名：Japanese journal of clinical oncology

    缩写：JPN J CLIN ONCOL

    ISSN：0368-2811

    e-ISSN：1465-3621

    IF/分区：2.2/Q3

    文章目录 更多期刊信息

    全文链接
    官方链接
    PMC全文
    引文链接
    复制
    已复制！
    推荐内容
    First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia